CD274 and neoplasm: The NADIM clinical trial NCT03081689T identified two parameters from TCR sequence analysis as predictive biomarkers of complete pathologic response (CPR) after neoadjuvant chemoimmunotherapy, which may be superior to the PD-L1 tumor proportional score (TPS) and TMB, and revealed the possible mechanism by which CPR is involved in enhancing tumor immunogenicity and peripheral immune monitoring (95).